circadian sleep/wake cycle process
Definition
Target type: biologicalprocess
A behavioral process involved in the cycle from wakefulness through an orderly succession of sleep states and stages that occurs on an approximately 24 hour rhythm. [GOC:isa_complete]
The circadian sleep/wake cycle is a complex biological process that regulates the timing of sleep and wakefulness over a roughly 24-hour period. This cycle is driven by an internal biological clock, known as the suprachiasmatic nucleus (SCN), located in the hypothalamus of the brain. The SCN receives light signals from the eyes, which synchronize the internal clock with the external environment. When light levels are low, the SCN signals the body to produce melatonin, a hormone that promotes sleep. As light levels increase, melatonin production decreases, and the body prepares for wakefulness. The SCN also influences other physiological processes, such as body temperature, hormone production, and alertness. The circadian sleep/wake cycle is crucial for maintaining physical and mental health, and disruptions to this cycle, such as shift work or jet lag, can have negative consequences on well-being.'
"
Proteins (1)
| Protein | Definition | Taxonomy |
|---|---|---|
| Orexin receptor type 2 | An orexin receptor type 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O43614] | Homo sapiens (human) |
Compounds (14)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| sb 408124 | SB 408124: a hypocretin receptor type 1 (HcrtR1) antagonist | organohalogen compound; quinolines | |
| sb 334867-a | 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea: selective OX1 receptor antagonist | naphthyridine derivative | |
| jnj 10397049 | JNJ 10397049: a selective orexin receptor-2 antagonist | ||
| sb674042 | SB674042: nonpeptide antagonist to the human orexin-1 receptor; structure in first source | ||
| tcs ox2 29 | |||
| almorexant | almorexant: a dual orexin receptor antagonist for treatment of insomnia | isoquinolines | |
| suvorexant | suvorexant : An aromatic amide obtained by formal condensation of the carboxy group of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid with the secondary amino group of 5-chloro-2-[(5R)-5-methyl-1,4-diazepan-1-yl]-1,3-benzoxazole. An orexin receptor antagonist used for the management of insomnia. suvorexant: an orexin receptor antagonist; structure in first source | 1,3-benzoxazoles; aromatic amide; diazepine; organochlorine compound; triazoles | central nervous system depressant; orexin receptor antagonist |
| mk-6096 | MK-6096: antagonist of orexin receptors 1 and 2; structure in first source | ||
| sb 649868 | N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide: antagonist of both orexin 1 and orexin 2 receptors; for treating insomnia; structure in first source | ||
| act-462206 | ACT-462206: an antagonist of both orexin 1 and oxexin 2 receptors; structure in first source | ||
| oroxin b | |||
| gsk 1059865 | |||
| act-335827 | |||
| orexin-a |